Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements

Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016 achievements.
“We expect 2017 to be a landmark year for Adamas,” said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “Our NDA for ADS-5102, a chrono-synchronous amantadine for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease, has now been accepted for filing by the FDA, and we are preparing for potential approval and commercialization. If approved, ADS-5102 will be the first and only medicine approved to treat levodopa-induced dyskinesia in Parkinson’s disease patients, which is an existing gap in their treatment journey. Additionally in 2017, we will continue to advance our clinical development programs, including ADS-5102 in multiple sclerosis walking impairment and ADS-4101, a chrono-synchronous lacosamide therapy, for partial onset seizures in epilepsy.”The Company’s key 2016 achievements and 2017 business priorities are summarized below.
ADS-5102 (amantadine hydrochloride) extended release capsules
ADS-5102 is a chrono-synchronous amantadine therapy for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Over time, 90% of patients on levodopa therapy will suffer from LID, which is characterized by involuntary movements that are purposeless and unpredictable. ADS-5102 is dosed once daily at bedtime to time the delivery of drug levels of amantadine to waking hours when LID episodes are most frequent and movement control is needed most. ADS-5102 for LID has been granted orphan drug status and the New Drug Application (NDA) is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of August 24, 2017. Adamas is also investigating ADS-5102 for other indications, as it may have broad utility in hyper- and hypokinetic disorders.